Search Results

You are looking at 71 - 80 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg

throughout the life cycle: treatment through the ages . Neurology 2004 ; 9 [ suppl 2 ]: S2 – S8 . 21 ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or

Full access

NCCN News

clinic. NCCN’s series of supportive care patient guidelines also includes books focused on side effects from treatment, such as nausea and vomiting, blood clots, anemia, and immunotherapy-related adverse events. There are also survivorship guidelines

Full access

NCCN Guidelines Raise Standards for Cancer Care Worldwide by Exceeding 10 Million Downloads in 2018 — Up 26% Over 2017

-Saharan Africa, plus 7 NCCN Harmonized Guidelines for the Caribbean. The topics they cover include cancer types such as breast, cervical, colon, lung, and prostate, plus issues such as how to manage pain, nausea, and palliative care. These guidelines—which are

Full access

Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

against targets will inform future quality improvement efforts. AB2013-13. Risk Factors for Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice After Moderately or Highly Emetogenic Chemotherapy: INSPIRE Study Nancy W. Peacock

Full access

Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger, and Adam M. Petrich

cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which were well tolerated except for nausea. She experienced a brief complete remission (CR), but quickly relapsed within 1 month. She received 3 cycles of etoposide

Full access

Nonhormonal Management of Hot Flashes for Women on Risk Reduction Therapy

Kostandinos Sideras and Charles L. Loprinzi

increased to target in the 75 and 150 mg/d groups. After 4 weeks, hot flashes were reduced by 27%, 37%, 61%, and 61%, respectively. The 150 mg dose was found to be associated with significantly more side effects, such as dry mouth, nausea, and constipation

Full access

Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis

Somasundaram Subramaniam, Jason A. Zell, and Pamela L. Kunz

he was developing worsening hand-foot syndrome. After a 4-month chemotherapy break, scans showed stable disease but he became increasingly symptomatic with abdominal discomfort, nausea, altered bowel habits, and chest and back pain. The authors

Full access

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Featured Updates to the NCCN Guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh

, but especially if the cough is dry or is coupled with shortness of breath, it could indicate pneumonitis . Headaches can be indicative of brain metastases, but when presenting with fatigue , visual symptoms , nausea , and other symptoms, may be

Full access

NCCN News

Patients: Nausea and Vomiting into the PatientPoint Interact Exam Room Program. PatientPoint is also promoting NCCN programs and evidence-based NCCN resources to patients, caregivers and oncology specialists. The collaboration, projected to reach more than

Full access

Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Robert A. Swarm, Judith A. Paice, Doralina L. Anghelescu, Madhuri Are, Justine Yang Bruce, Sorin Buga, Marcin Chwistek, Charles Cleeland, David Craig, Ellin Gafford, Heather Greenlee, Eric Hansen, Arif H. Kamal, Mihir M. Kamdar, Susan LeGrand, Sean Mackey, M. Rachel McDowell, Natalie Moryl, Lisle M. Nabell, Suzanne Nesbit, BCPS, Nina O’Connor, Michael W. Rabow, Elizabeth Rickerson, Rebecca Shatsky, Jill Sindt, Susan G. Urba, Jeanie M. Youngwerth, Lydia J. Hammond, and Lisa A. Gurski

tetrahydrocannabinol [THC] or THC-mimics) have been approved to treat refractory nausea and vomiting associated with cancer treatment, dronabinol has also been approved to treat anorexia and weight loss related to AIDS. Cannabidiol has been approved to treat seizures